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PROBLEM IDENTIFICATION
• An estimated 50 million Americans or 20% of adults in the US have chronic pain. An 
additional 19.6 million Americans have high-impact chronic pain11
• Chronic pain is reported at higher rates among adults who are women, older than 65 
years of age, unemployed, living in poverty, insured with public health insurance, 
and residents of rural areas11
• According to the Anxiety and Depression Association of American, 40 million adults 
in the US, or 18%, suffer from anxiety. Anxiety disorders are the most common mental 
illness in the US12
• Problems with falling asleep or daytime sleepiness affect approximately 35 to 40% of 
the U.S. adult population annually and are a significant cause of morbidity and 
mortality13
• As of March 2018, there were 5,571 patients enrolled in the Vermont Marijuana 
Registry. Qualifying conditions include cancer, multiple sclerosis, positive status for 
human immunodeficiency virus, acquired immune deficiency syndrome, glaucoma, 




• In 2017, an ad hoc committee of the National Academies of Science, 
Engineering, and Medicine published the report The Health Effects of 
Cannabis and Cannabinoids: The Current State of Evidence and 
Recommendations for Research. In the report, the committee presented 
nearly 100 conclusions related to the health effects of medical cannabis. 
Some of their conclusions include:
• There is conclusive or substantial evidence that cannabis or cannabinoids are 
effective for the treatment of chronic pain in adults
• There is moderate evidence that cannabis or cannabinoids are effective for 
improving short term sleep outcomes in individuals with sleep disturbance 
associated with sleep apnea syndrome, fibromyalgia, chronic pain, and multiple 
sclerosis
• There is limited evidence that cannabis or cannabinoids are effective for 
improving anxiety symptoms and symptoms of PTSD.
DESCRIPTION OF NEED
• “I have patients ask me about medical marijuana and CBD all the time. I just 
don’t know enough about it to feel really comfortable recommending it. It 
would be super helpful to have more information about potentially using 
medical cannabis as an alternative to less desirable medications for things 
like pain and insomnia” – Robert Luebbers, MD
• The number of opioid related fatalities has continued to rise with 33% of 
opioid related deaths in 2017 caused by prescription opiates.15
• 62% of Vermonters using medical cannabis have chronic pain.16
• 28.2% of Vermonters using medical cannabis have been diagnosed with an 
anxiety disorder.16
• 22.5% of Vermonters using medical cannabis have been diagnosed with 
insomnia or another sleep disorder.16
PUBLIC HEALTH 
COSTS
• The total cost of pain to society 
combining healthcare cost 
estimates and three productivity 
estimates ranges from $560 - $635 
billion dollars annually.17
• Insufficient sleep costs $411 billion 
dollars annually, 2.28% of the United 
States GDP.18
• Federally, medical cannabis is 
considered a Schedule 1 
substance. In Vermont, state 
legislature legalized the use of 
homegrown and medical cannabis. 
Because of this discrepancy, data 
on the public health costs of 
medical cannabis use is lacking.
Hafner et al. 2017
COMMUNITY PERSPECTIVE 
AND SUPPORT #1
• My first community interview took place with Ada Puches, the Community Outreach 
Coordinator for Champlain Valley Dispensaries and Southern Vermont Wellness. Ms. 
Puches provided me with a folder full of resources highlighting the scientific 
evidence behind the use of medical cannabis. She was extremely excited to learn 
about the project to help medical providers learn more about her field. She 
instructed me on the requirements for qualifying conditions for medical marijuana by 
Vermont State Law and educated me regarding the regulations faced by 
dispensaries in Vermont. She also helped me learn about the routes of administration 
of varying medical cannabis products and how the different products can be useful 
for different chief complaints. 
• “I love working in the field of medical cannabis because I have so much opportunity 
to help people. Most of my clients are using medical cannabis for pain, but a large 
portion of them use our products for help with sleep. Medical cannabis is so much 
safer than [for example] fentanyl patches and I’m glad that health care providers 
are interested in learning more.
• -Ada Puches, Community Outreach Coordinator, Champlain Valley Dispensaries 
COMMUNITY PERSPECTIVE 
AND SUPPORT #2
• My second community interview was with Paul Jerard, PA-C who runs the Vermont 
Cannabinoid Clinic providing medical guidance for medicinal cannabis. Mr. Jerard
started working in the field of medical cannabis after speaking with some friends in 
Colorado who were doing similar advising. He realized that there was a need in 
Vermont for medical guidance and support for providers, so he started the Vermont 
Cannabinoid Clinic. Mr. Jerard was instrumental to my understanding of the 
pharmacology, adverse effects, and dosing suggestions for both THC and CBD 
products. He receives consults from other health care providers in order to help their 
patients manage their chronic conditions with medical cannabis. Most of his 
patients have several chronic conditions and are interested in exploring cannabis as 
an alternative therapy to more traditional allopathic medications.
• “The type of cannabis that I usually suggest for most people is the cannabis with THC 
and CBD in a 1:1 ratio. CBD augments the psychoactive effects of THC and keeps 
people from feeling as high. You also get the anti-inflammatory effects from the CBD. 
It’s important to start at a low dose and titrate up. Start with 2mg of THC and 
increase the dose by 0.5mg every 2-3 days until symptoms have improved
• -Paul Jerard, PA-C, Vermont Cannabinoid Clinic
INTERVENTION AND METHODOLOGY
• I constructed an educational handout for medical providers discussing the scientific 
evidence behind the therapeutic effects of medical cannabis focusing on THC and 
CBD. The handout includes information on pharmacology, drug interactions, 
contraindications, adverse effects, routes of administration, and dosing 
recommendations for THC, CBD, and THC/CBD combinations. I also included 
information specific to ensuring that patients could purchase high quality CBD-rich 
oils from respected sources.
• A two question before handout survey was administered to 6 providers prior to their 
reviewing the handout. After the providers reviewed the handout, they completed 
an additional two question after handout survey to assess for the effectiveness of the 
handout.
• All 6 providers where medical doctors working at the UVMMC Family Medicine Clinic 
in South Burlington






• Response to the handout was 
positive! 
• Comfort level with 
recommending medical 
cannabis increased by 2 points 
after providers reviewed the 
handout
• Likelihood of recommending 
medical cannabis increased by 
1.8 points after providers 
reviewed the handout 
• 100% of providers said they 
would use the information from 













Comfort Level with Recommending Medical Cannabis Liklihood of Recommending Medical Cannabis
Effectiveness of Intervention Survey
Before Handout After Handout

EVALUATION OF EFFECTIVENESS 
AND LIMITATIONS
• Based on my preliminary results, I can conclude that my handout was effective at 
increasing provider confidence and liklihood in recommending medical cannabis as 
therapeutic intervention for evidence based indications.
• Anecdotally, many providers in Vermont would like to find an effective alternative to 
prescribing medications like opiates and benzodiazepines for chronic pain and anxiety, 
respectively. I can conclude that my intervention was effective at increasing provider 
knowledge base given the 100% provider response that they will use the information in 
their future practice.
• My current sample size for evaluation of effectiveness is small. Increasing the sample size 
would increase the power of the study and increase confidence in the effectiveness of 
the handout.
• Limitations:
• Small sample size – 6 providers were surveyed
• Current legislation and regulations do not provide adequate assurance that THC or CBD 
products contain what is advertised on the label. Quality control is currently regulated by the 
state for medical marijuana and is not regulated at all for CBD. Providers have to ensure that 
patients are aware of the possibility of failed drug testing while using medical cannabis 
products.
• There was not enough time during the 6 week family medicine clerkship to evaluate the future 
implications of increased provider education on this topic.
RECOMMENDATIONS FOR FUTURE 
INTERVENTIONS AND PROJECTS
• Increase distribution of the hand out among family medicine providers in the 
UVM Health Network
• Distribute the handout to other providers not associated with Family 
Medicine. Providers in every field of medicine will care for patient with 
chronic pain, anxiety, sleep issues, etc.
• Future medical students can track the number of times that providers 
recommend medical cannabis to their patients for conditions backed by 
scientific evidence. If the number of recommendations increases, it is likely 
that this is secondary to increased knowledge gained from the handout.
• The field of medical cannabis is a burgeoning field of research with new 
evidence published daily. A future medical student could update the 
handout based on the most up to date information annually following 
publishing of new high quality evidence.
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CONSENT FOR INTERVIEWS
• Thank you for agreeing to be interviewed. This project is a requirement for 
the Family Medicine clerkship. It will be stored on the Dana Library 
ScholarWorks website. Your name will be attached to your interview and you 
may be cited directly or indirectly in subsequent unpublished or published 
work. The interviewer affirms that he/she has explained the nature and 
purpose of this project. The interviewee affirms that he/she has consented to 
this interview. Yes __x___ / No _____ If not consenting as above: please add 
the interviewee names here for the department of Family Medicine 
information only. Name: __Ada Puches, Community Outreach Coordinator, 
Champlain Valley Dispensary
• Name: Paul Jerard, PA-C, Vermont Cannabinoid Clinic
